Michel Vounatsos, Biogen CEO (via YouTube)
Biogen's Michel Vounatsos takes home $18.7M in pay as the company battles to take aducanumab to market
Biogen found itself at the center of controversy late last year as it worked with the FDA to grease the wheels for its controversial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
